Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience reports company news on its life science research tools business, which develops, manufactures and sells technologies, products and services for research, pharmaceutical and therapy discovery, bioproduction and preclinical testing. Updates commonly cover operating and financial results, new products for translational science, New Approach Methodologies, product mix, and customer markets that include academic institutions, government laboratories, pharmaceutical companies, biotechnology companies and contract research organizations.
Company releases also address capital actions, Nasdaq listing compliance, manufacturing and operating-model changes, management appointments, guidance, and investor conference presentations. The business sells through direct and distribution channels and has operations in the United States, Europe and China.
Harvard Bioscience (Nasdaq: HBIO) has successfully closed a new $65 million credit facility, refinancing existing debt to enhance liquidity and reduce borrowing costs. This refinancing will yield over $2 million in annual cash interest savings starting in 2021 while providing greater operational flexibility through less restrictive covenants. The facility includes a $40 million term loan and a $25 million senior revolving credit line, aimed at supporting the company's transition into a profitable growth platform.
Harvard Bioscience (Nasdaq: HBIO) will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference on November 18, 2020. CEO Jim Green and CFO Michael Rossi will engage in virtual meetings throughout the day. Interested investors can schedule a meeting by contacting their Benchmark representative or directly reaching out to Vince Curatola. Presentation materials will be available on the company’s investor relations page that same day at 8:00 AM ET. Harvard Bioscience specializes in technologies for drug development and serves a wide range of global customers.
Harvard Bioscience (Nasdaq: HBIO) reported Q3 2020 financial results showing improved operating income and reduced net debt year-over-year. Revenue rose sequentially to $24.0 million, supported by demand from CRO/pharma and the reopening of academic labs. Adjusted operating income was $3.6 million, with an operating margin of 14.8%. The company anticipates continued growth, forecasting mid to upper teen operating margins for the second half of 2020, driven by disciplined cost management and targeted investments.
Harvard Bioscience (Nasdaq: HBIO) will release its Q3 financial results for the period ended September 30, 2020 before the market opens on November 5, 2020. A conference call to discuss these results will take place on the same day at 8:00 a.m. ET. Participants can join the call via toll-free dial-in or access the live webcast on the company’s website. Financial information and related materials will be available in the Investor Relations section of the site.
Harvard Bioscience (Nasdaq: HBIO) announced that CEO Jim Green will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020, at 2:15 p.m. ET. The presentation will be accessible online via a registration link provided by Singular Research. A slide deck for the webinar will also be available on the company's Investor Relations page. Harvard Bioscience specializes in developing technologies and products for drug development, serving a diverse clientele ranging from academic institutions to major pharmaceutical companies globally.
Harvard Bioscience, Inc. (Nasdaq: HBIO) reported Q2 2020 results showing a revenue of $23.3 million, down from $29.6 million in Q2 2019. Despite this decline, operating income improved to $0.6 million (GAAP) from a loss of $3.3 million in Q1 2020. Adjusted operating income reached $4.1 million with a margin of 17.7%. The company reduced net debt by $2.2 million to $42.1 million. CEO Jim Green noted that cost reduction initiatives have effectively offset expected revenue declines in academic markets, enabling growth from CRO/pharma clients and improved operating margins.
Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its financial results for the second quarter ending June 30, 2020, on August 5, 2020, before the market opens. A conference call will take place the same day at 8:00 a.m. Eastern Time, accessible via toll-free and international numbers with a conference ID of #4458189. The call will also be webcast on the company’s investor relations website. Harvard Bioscience specializes in technologies for fundamental research and drug development, serving academic institutions, government labs, and leading pharmaceutical firms across North America and Europe.
Harvard Bioscience (Nasdaq: HBIO) has updated shareholders on its strategic initiatives aimed at long-term growth, despite challenges posed by COVID-19. The company reported increased demand for research products related to the pandemic. Key strategic actions from September 2019 are on track, including a $6 million debt reduction, improved margins, and a streamlined manufacturing process. Harvard Bioscience also emphasizes efforts to support research organizations in developing COVID-19 treatments and vaccines. Overall, they remain committed to creating shareholder value as they navigate current challenges.
Harvard Bioscience (Nasdaq: HBIO) reported Q1 2020 revenue of $23.8 million, down 16% year-over-year due to the Covid-19 pandemic. The company experienced a gross margin of 54.6% but faced an operating loss of $3.3 million, compared to a loss of $0.1 million in Q1 2019. Adjusted loss per share was $(0.01), down from $0.02 in the previous year. Cash flow from operations was $2.9 million, with a $5 million debt reduction. The company has retracted its full-year 2020 guidance, anticipating a revenue decline of 20%-30% in Q2.